These findings, therefore, provide a rationale for evaluating fetuin-A and fetuin-B in the pathophysiological process of NAFLD, and might open up new perspectives in early diagnosis, identification of novel biomarkers, and providing novel targets for pharmacological interventions. This evidence concerns the gene AHSG and metabolic dysfunction-associated steatotic liver disease.